On April 28, 2008, a nationwide Digitek recall was announced for all lots of the heart medication sold throughout the United States under the “Bertek” and “UDL” labels.
New cases are no longer being accepted. This page is maintained for informational purposes only.
Due to manufacturing defects, Digitex (digoxin tablets) could contain twice the appropriate amount of active ingredients. This could lead to serious and potentially fatal illness caused by overmedication, especially among individuals with renal insufficiencies.
The lawyers at Saiontz & Kirk, P.A. are no longer reviewing potential Digitek lawsuits throughout the United States.
Digitex tablets are prescribed for treatment of heart failure and abnormal heart rhythms. The generic form of digitalis were manufactured by Actavis Totowa, formerly known as Amide Pharmaceutical, Inc., a division of Actavis Group. The tablets were distributed by Mylan Pharmaceuticals, Inc. under the “Bertek” label and by UDL Laboratories, Inc. under the “UDL” labels. Actais manufactures approximately half of the digoxin sold in the United States.
A nationwide Digitek recall was announced after it was discovered that manufacturing errors could have allowed twice as the amount of active ingredients to be placed in tablets sold to consumers. Reports suggest that the defective Digitek tablets may have been sold for over a year.
The Digitek recall has been classified as a Class 1 Recall, which means that the product poses a substantial risk of serious injury or death. For individuals with renal failure or impaired kidney function, they could suffer from a potentially fatal illness known as Digitalis Toxicity. This occurs when excessive amounts of digitalis accumulates in the body.
Digitek overdose symptoms could include:
- Low Blood Pressure
- Cardiac Instability
- Bradycardia (slow heartbeat)
DIGITEK CLASS ACTION SUITS AND INDIVIDUAL LAWSUITS
The Digitek lawyers at Saiontz & Kirk, P.A. previously reviewed potential individual lawsuits on behalf of individuals who received a prescription for Digitek (digoxin tablets) since 2006 and required medical treatment as a result of digitalis toxicity. Negligence in the manufacturing process has exposed people, particularly those with renal impairment, to a risk of serious and potentially fatal illness.
New cases are no longer being accepted by Saiontz & Kirk, P.A. This page is maintained for informational purposes only.